Supernus Pharmaceuticals (SUPN) Cash from Operations (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Cash from Operations of 4810000.0 for Q2 2026, down 108.22% year-over-year from 58535000.0 in Q2 2025, and down 107.23% on a QoQ basis from 66524000.0 in Q1 2026.
Supernus Pharmaceuticals (SUPN) Cash from Operations (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Cash from Operations for 16 years, with the latest figure at 4810000.0 in Q2 2026.
- Cash from Operations for Q2 2026 came in at 4810000.0, down 108.22% year-over-year; the trailing twelve-month figure through Jun 2026 was 19911000.0 (down 89.36% YoY), and the FY2025 annual result was 47331000.0, down 72.47% from the prior year.
- Cash from Operations slipped to 4810000.0 in Q2 2026, from 66524000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 71119000.0 in Q2 2022 and troughed at 61664000.0 in Q3 2025.
- A 5-year average of 28272611.11 and a median of 35749500.0 in 2023 frame the typical range for Cash from Operations.
- The widest annual swing landed in 2023, when Cash from Operations soared 1041.93%; it then sank 215.22% in 2025.
- A 5-year view of Cash from Operations shows it stood at 27564000.0 in 2022, then surged by 63.1% to 44958000.0 in 2023, then dropped by 1.23% to 44406000.0 in 2024, then tumbled by 55.27% to 19861000.0 in 2025, then sank by 124.22% to 4810000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 4810000.0 in Q2 2026, 66524000.0 in Q1 2026, and 19861000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.67 Bn | 2.30 Bn | 185.39 Mn | -4.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.81 Mn |
| Jun 30, 2026 | -4.81 Mn |
| Mar 31, 2026 | 66.52 Mn |
| Mar 31, 2026 | 66.52 Mn |
| Dec 31, 2025 | 19.86 Mn |
| Dec 31, 2025 | 19.86 Mn |
| Sep 30, 2025 | -61.66 Mn |
| Sep 30, 2025 | -61.66 Mn |
| Jun 30, 2025 | 58.54 Mn |
| Jun 30, 2025 | 58.54 Mn |
| Mar 31, 2025 | 30.60 Mn |
| Mar 31, 2025 | 30.60 Mn |
| Dec 31, 2024 | 44.41 Mn |
| Dec 31, 2024 | 44.41 Mn |
| Sep 30, 2024 | 53.52 Mn |
| Sep 30, 2024 | 53.52 Mn |
| Jun 30, 2024 | 35.62 Mn |
| Jun 30, 2024 | 35.62 Mn |
| Mar 31, 2024 | 38.40 Mn |
| Mar 31, 2024 | 38.40 Mn |